3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Liposarcoma
1
Interventions
Doxorubicin
7
Radiotherapy
4
Radiation
3
Magnetic Resonance Spectroscopy
3
Ifosfamide
3
regorafenib
2
Temozolomide
2
Surgical Procedures, Operative
2
Methotrexate
2
Imatinib Mesylate
2
Etoposide
2
Drug Therapy
2
Cyclophosphamide
2
Cisplatin
2
veliparib
1
selinexor
1
pirarubicin
1
pazopanib
1
niraparib
1
merphos
1
liposomal doxorubicin
1
fludarabine phosphate
1
dostarlimab
1
capmatinib
1
cabozantinib
1
brigimadlin
1
apatinib
1
anlotinib
1
Zoledronic Acid
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Sugars
×
Sarcoma
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts